FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296385644> ?p ?o ?g. }

• W4296385644 endingPage "S195" @default.
• W4296385644 startingPage "S195" @default.
• W4296385644 abstract "Introduction: Cellular and humoral response are required for the SARS-CoV-2 eradication. Antigen presenting cells load SARS-CoV-2 peptides on human leukocyte antigen with different avidity and present to T and B cells for the differential humoral and cellular response. Due to immunosuppression, renal transplant recipient patients are speculated to poorly form the antibody against SARS-CoV-2 virus. Therefore, determining the association of specific HLA alleles with anti-SARS-CoV-2 spike protein antibody formation will be helpful in managing the renal transplant recipient patients having specific HLA alleles from SARS-CoV-2 infection and vaccination. Material and Methods: In this study anti-SARS-CoV-2 spike protein antibody in 161 renal allograft recipient patients were determined by the chemiluminescent microparticle immunoassay methods and human leukocyte antigen alleles were determined by the polymerase chain reaction-single strand oligonucleotide methods and analyzed to study, the HLA alleles association with anti-SARS-CoV-2 spike protein humoral response and severity of COVID-19 symptoms in recently SARS-CoV-2 infected patients. Seroconversion was defined if anti-SARS-CoV-2 spike protein antibody titer was >50AU/ml. Results: The anti-SARS-CoV-2 spike protein antibody seroconversion rate in renal allograft recipients was 90.06% with median titer 751.80 AU/ml. The frequency of HLA class I alleles A*11 was in 22.1%, A*24 in 21.37%, A*33 in 20.68%, HLA B*15 in 11%, B*07 in 8.27%, HLA-C*30 in 20.93% and C*70 in 23.25% and Class II HLA alleles -DRB1*07 was in 18.62%, DRB1*04 in 13.8%, HLA-DRB1*10 in 14.48% and HLA-DQA1*50 in 32.55% of patient and were associated with the seroconversion.HLA-B*04, B*52, and B*55 were associated with non-seroconversion in 18.75%, 12.5 and 6.25% of patients respectively, HLA- C*07, C*12, C*30 in 16.6% of patients and C*60 in 33.3% of patients were associated with non-seroconversion. HLA-DRB1*01, HLA-DRB1*03 in 12.5% and DRB1*70 in 6.25% of patients were associated with non- seroconversion. The mean post-infection time of patients recovery from COVID19 symptoms was 18.25±8.14 days. Conclusion: Renal transplant recipients with SARS-CoV-2 infection developed a robust seroconversion rate of 90.0% and different alleles of HLA-B, DRB1 and DQA1 were significantly associated with the seroconversion." @default.
• W4296385644 created "2022-09-20" @default.
• W4296385644 creator A5002564954 @default.
• W4296385644 creator A5037021190 @default.
• W4296385644 creator A5041781876 @default.
• W4296385644 creator A5068104617 @default.
• W4296385644 creator A5077033489 @default.
• W4296385644 creator A5078433275 @default.
• W4296385644 creator A5086305130 @default.
• W4296385644 date "2022-09-01" @default.
• W4296385644 modified "2023-10-18" @default.
• W4296385644 title "310.6: Association of Human Leukocyte Antigen With Anti-sARS-cov-2 Spike Protein Humoral Response" @default.
• W4296385644 doi "https://doi.org/10.1097/01.tp.0000886352.06541.2b" @default.
• W4296385644 hasPublicationYear "2022" @default.
• W4296385644 type Work @default.
• W4296385644 citedByCount "0" @default.
• W4296385644 crossrefType "journal-article" @default.
• W4296385644 hasAuthorship W4296385644A5002564954 @default.
• W4296385644 hasAuthorship W4296385644A5037021190 @default.
• W4296385644 hasAuthorship W4296385644A5041781876 @default.
• W4296385644 hasAuthorship W4296385644A5068104617 @default.
• W4296385644 hasAuthorship W4296385644A5077033489 @default.
• W4296385644 hasAuthorship W4296385644A5078433275 @default.
• W4296385644 hasAuthorship W4296385644A5086305130 @default.
• W4296385644 hasBestOaLocation W42963856441 @default.
• W4296385644 hasConcept C147483822 @default.
• W4296385644 hasConcept C159047783 @default.
• W4296385644 hasConcept C159654299 @default.
• W4296385644 hasConcept C188280979 @default.
• W4296385644 hasConcept C203014093 @default.
• W4296385644 hasConcept C22889606 @default.
• W4296385644 hasConcept C2776548049 @default.
• W4296385644 hasConcept C2777451964 @default.
• W4296385644 hasConcept C32611913 @default.
• W4296385644 hasConcept C71924100 @default.
• W4296385644 hasConcept C86803240 @default.
• W4296385644 hasConceptScore W4296385644C147483822 @default.
• W4296385644 hasConceptScore W4296385644C159047783 @default.
• W4296385644 hasConceptScore W4296385644C159654299 @default.
• W4296385644 hasConceptScore W4296385644C188280979 @default.
• W4296385644 hasConceptScore W4296385644C203014093 @default.
• W4296385644 hasConceptScore W4296385644C22889606 @default.
• W4296385644 hasConceptScore W4296385644C2776548049 @default.
• W4296385644 hasConceptScore W4296385644C2777451964 @default.
• W4296385644 hasConceptScore W4296385644C32611913 @default.
• W4296385644 hasConceptScore W4296385644C71924100 @default.
• W4296385644 hasConceptScore W4296385644C86803240 @default.
• W4296385644 hasIssue "9S" @default.
• W4296385644 hasLocation W42963856441 @default.
• W4296385644 hasLocation W42963856442 @default.
• W4296385644 hasOpenAccess W4296385644 @default.
• W4296385644 hasPrimaryLocation W42963856441 @default.
• W4296385644 hasRelatedWork W1539989077 @default.
• W4296385644 hasRelatedWork W1977392131 @default.
• W4296385644 hasRelatedWork W1984647379 @default.
• W4296385644 hasRelatedWork W2148908215 @default.
• W4296385644 hasRelatedWork W2348343045 @default.
• W4296385644 hasRelatedWork W2408800779 @default.
• W4296385644 hasRelatedWork W2414181163 @default.
• W4296385644 hasRelatedWork W3000660023 @default.
• W4296385644 hasRelatedWork W3202566745 @default.
• W4296385644 hasRelatedWork W3217227264 @default.
• W4296385644 hasVolume "106" @default.
• W4296385644 isParatext "false" @default.
• W4296385644 isRetracted "false" @default.
• W4296385644 workType "article" @default.